{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04445454",
      "OrgStudyIdInfo": {
        "OrgStudyId": "TJT2012"
      },
      "Organization": {
        "OrgFullName": "University of Liege",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection",
      "OfficialTitle": "Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection"
    },
    "StatusModule": {
      "StatusVerifiedDate": "August 2021",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "June 12, 2020",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "September 30, 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "September 30, 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "June 19, 2020",
      "StudyFirstSubmitQCDate": "June 22, 2020",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "June 24, 2020",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "August 31, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "September 1, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Yves Beguin",
        "ResponsiblePartyInvestigatorTitle": "MD,PhD",
        "ResponsiblePartyInvestigatorAffiliation": "University of Liege"
      },
      "LeadSponsor": {
        "LeadSponsorName": "University of Liege",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The overall objective of the study is to evaluate the safety and efficacy of MSC therapy combined with best supportive care in hospitalized patients with COVID-19.",
      "DetailedDescription": "This study is a monocentric prospective phase I/II clinical trial, aiming at evaluating the safety and efficacy of 3 intravenous administrations of BM-MSC in 20 patients with severe to critical COVID-19 pneumonia.\n\nAfter signed informed consent, patients will receive 3 infusions of (1.5)-3.0 x106/kg BM-MSC (from the same donor) at 3-4 days interval, in addition to the standard of care for COVID-19 disease.\n\nThe trial will be open for inclusion for 2 years after initiation. Each patient will be followed for 90 days after inclusion. The total study duration will thus be 2 years and 90 days."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Coronavirus Infection"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "mesenchymal stromal cells"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignInterventionModelDescription": "This study is a monocentric prospective phase I/II clinical trial, aiming at evaluating the safety and efficacy of 3 intravenous administrations of BM-MSC in 20 patients with severe to critical COVID-19 pneumonia.",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "20",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "MSC therapy for severe COVID-19 infection",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "After signed informed consent, patients will receive 3 infusions of (1.5)-3.0 x106/kg BM-MSC (from the same donor) at 3-4 days interval, in addition to the standard of care for COVID-19 disease.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Mesenchymal stromal cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Mesenchymal stromal cells",
            "InterventionDescription": "Bone marrow collection and MSC expansion cultures will be carried out at the Laboratory of Cell and Gene Therapy (LTCG) at the University of Li√®ge as described in IMPD and its SOPs.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "MSC therapy for severe COVID-19 infection"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "MSC"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "To evaluate the safety of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia",
            "PrimaryOutcomeDescription": "To assess the infusional toxicity",
            "PrimaryOutcomeTimeFrame": "Day 28"
          },
          {
            "PrimaryOutcomeMeasure": "To evaluate the safety of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia",
            "PrimaryOutcomeDescription": "To assess the number of Adverse events of special interest : Incidence of infections (bacterial, viral, fungal, parasitic) and thrombo-embolic events.",
            "PrimaryOutcomeTimeFrame": "Day 28"
          },
          {
            "PrimaryOutcomeMeasure": "To evaluate the efficacy of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia",
            "PrimaryOutcomeDescription": "Group A (patients not under mechanical ventilation): to determine the pourcentage of patients requiring mechanical ventilation",
            "PrimaryOutcomeTimeFrame": "Day 28"
          },
          {
            "PrimaryOutcomeMeasure": "To evaluate the efficacy of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia",
            "PrimaryOutcomeDescription": "Group B (patients under mechanical ventilation): to determine the vital status (dead/alive)",
            "PrimaryOutcomeTimeFrame": "Day 28"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
            "SecondaryOutcomeDescription": "To assess the clinical status (on a 7-point WHO ordinal scale)",
            "SecondaryOutcomeTimeFrame": "Day 28"
          },
          {
            "SecondaryOutcomeMeasure": "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
            "SecondaryOutcomeDescription": "To assess the duration of oxygen therapy and/or mechanical ventilation",
            "SecondaryOutcomeTimeFrame": "Day 28"
          },
          {
            "SecondaryOutcomeMeasure": "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
            "SecondaryOutcomeDescription": "To assess the length of stay at the intensive care unit and of hospitalization",
            "SecondaryOutcomeTimeFrame": "Day 90"
          },
          {
            "SecondaryOutcomeMeasure": "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
            "SecondaryOutcomeDescription": "To assess the number of organ failures",
            "SecondaryOutcomeTimeFrame": "Day 28"
          },
          {
            "SecondaryOutcomeMeasure": "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
            "SecondaryOutcomeDescription": "To assess the intensity of the inflammatory response",
            "SecondaryOutcomeTimeFrame": "Day 28"
          },
          {
            "SecondaryOutcomeMeasure": "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
            "SecondaryOutcomeDescription": "To assess the evolution of coagulation parameter",
            "SecondaryOutcomeTimeFrame": "Day 28"
          },
          {
            "SecondaryOutcomeMeasure": "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
            "SecondaryOutcomeDescription": "To assess the presence of Biomarker of lung lesion, repair and scarring",
            "SecondaryOutcomeTimeFrame": "Day 28"
          },
          {
            "SecondaryOutcomeMeasure": "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
            "SecondaryOutcomeDescription": "To assess the v iral load over the 28 days after inclusion and seroconversion to COVID-19 over the 90 days after inclusion",
            "SecondaryOutcomeTimeFrame": "Day 90"
          },
          {
            "SecondaryOutcomeMeasure": "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
            "SecondaryOutcomeDescription": "To assess the pulmonary function",
            "SecondaryOutcomeTimeFrame": "Day 90"
          },
          {
            "SecondaryOutcomeMeasure": "To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy)",
            "SecondaryOutcomeDescription": "To assess the number of adverse reactions (ARs), ARs grade > 3, serious adverse events (SAEs), serious ARs (SARs), suspected expected and unexpected SARs (SESARs and SUSARs).",
            "SecondaryOutcomeTimeFrame": "Day 90"
          }
        ]
      },
      "OtherOutcomeList": {
        "OtherOutcome": [
          {
            "OtherOutcomeMeasure": "To investigate immune modulation",
            "OtherOutcomeDescription": "To determine the FACS analysis of regulatory T-cell (Treg) levels and Treg and Tconv sub-populations",
            "OtherOutcomeTimeFrame": "Day 28"
          },
          {
            "OtherOutcomeMeasure": "To compare the cytotoxic activity of PBMCs from healthy control and COVID-19 patients (divided in responders / non-responders to MSC therapy) against MSCs in vitro",
            "OtherOutcomeDescription": "To assess the cytotoxic activity by MLR",
            "OtherOutcomeTimeFrame": "Day 28"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "COVID-19 patients Inclusion criteria\n\nMale or female patients aged at least 18 years and up to 70 years\nDiagnosed with microbiologically or radiologically confirmed COVID-19 pneumonia as defined by:\nExtensive interstitial pneumonia on CT scan, consistent with viral pneumonia, within 10 days prior to randomization\nAnd either positive result of COVID-19 PCR test within 14 days prior to inclusion or positive result of SARS-CoV2 PCR or serology within 14 days after inclusion.\n\nRequiring oxygen administration (SpO2 ‚â§ 93% on room air):\n\nGroup A: in standard or intensive care unit requiring supplemental oxygen\nGroup B: in intensive care unit under mechanical ventilation administered through a tracheal tube, either:\nfor less than or equal to 7 days\nfor 7 to 14 days, with persisting high inflammation (ferritin > 2,000 ¬µg/L; ferritin > 1,000 ¬µg/L and rising; lymphocytes < 800 with CRP > 70 mg/L and rising or ferritin > 700 ¬µg/L and rising or LDH > 300 UI/L or D-Dimers > 1000 ng/ml), not explained by superinfection. Rising = compared to previous 24H.\nWritten consent of the patient, or - if impossible (clinical condition precluding capacity to consent) - of his/her legal representative, or - if impossible - of an impartial witness such as a physician from a non-participating department or member of the Ethics Committee. Any consent obtained this way shall be documented and confirmed by way of normal consent procedures at the earliest opportunity when the patient has recovered\n\nExclusion criteria\n\nOngoing pregnancy. Women of childbearing potential (WOCBP, defined as a premenopausal female capable of becoming pregnant) should use an appropriate method of contraception (oral, injectable, or mechanical contraception; women whose partners have been vasectomized or have received or are utilizing mechanical contraceptive devices).\nExtracorporeal membrane oxygenation\nLimitations to intensity of care\nLife expectancy < 24 hours\nKnown allergy to IMP component\nPre-existing bone marrow transplant or immunosuppressive therapy\nActive secondary infection\nAny malignancy (except non-melanoma skin carcinoma) within 2 years before inclusion\nPre-existing thrombo-embolic pathology\nSigns of an active drug or alcohol dependence, serious current illness, mental illness or any factors which, in the opinion of the Investigator, may interfere with subject's ability to understand and comply with study requirements\nPatients with any serious medical condition or abnormality of clinical laboratory tests that, in the Investigator's judgment, precludes the patient's safe participation in and completion of the study.\nParticipation in another clinical trial(use of anti-viral/supportive drugs for COVID-19 infection on a compassionate use basis is not an exclusion criterion).\n\nMSC donors Inclusion criteria\n\nUnrelated to the patient\nMale or female\nAge > 18 yrs\nNo HLA matching required\nFulfills generally accepted criteria for allogeneic HSC donation\nInformed consent given by donor\n\nExclusion criteria\n\nAny condition not fulfilling inclusion criteria\nKnown allergy to lidocaine\nAny risk factor for transmissible infectious diseases, in particular HIV",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "70 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Yves Beguin, MD,PhD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "(0032)43667201",
            "CentralContactEMail": "yves.beguin@chuliege.be"
          },
          {
            "CentralContactName": "Audrey Janssen",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "(0032)43667470",
            "CentralContactEMail": "audrey.janssen@chuliege.be"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Yves Beguin, MD,PhD",
            "OverallOfficialAffiliation": "CHU de Li√®ge",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "CHU de Li√®ge",
            "LocationStatus": "Recruiting",
            "LocationCity": "Li√®ge",
            "LocationZip": "4000",
            "LocationCountry": "Belgium",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Yves Beguin, MD,PhD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "(0032)43667201",
                  "LocationContactEMail": "yves.beguin@chuliege.be"
                },
                {
                  "LocationContactName": "Benoit Misset, MD,PhD",
                  "LocationContactRole": "Sub-Investigator"
                },
                {
                  "LocationContactName": "Nathalie Layios, MD",
                  "LocationContactRole": "Sub-Investigator"
                },
                {
                  "LocationContactName": "Bernard Lambermont, MD,PhD",
                  "LocationContactRole": "Sub-Investigator"
                },
                {
                  "LocationContactName": "Michel Moutschen, MD,PhD",
                  "LocationContactRole": "Sub-Investigator"
                },
                {
                  "LocationContactName": "Gilles Darcis, MD,PhD",
                  "LocationContactRole": "Sub-Investigator"
                }
              ]
            }
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000007239",
            "ConditionMeshTerm": "Infections"
          },
          {
            "ConditionMeshId": "D000003141",
            "ConditionMeshTerm": "Communicable Diseases"
          },
          {
            "ConditionMeshId": "D000018352",
            "ConditionMeshTerm": "Coronavirus Infections"
          },
          {
            "ConditionMeshId": "D000086382",
            "ConditionMeshTerm": "COVID-19"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000020969",
            "ConditionAncestorTerm": "Disease Attributes"
          },
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000003333",
            "ConditionAncestorTerm": "Coronaviridae Infections"
          },
          {
            "ConditionAncestorId": "D000030341",
            "ConditionAncestorTerm": "Nidovirales Infections"
          },
          {
            "ConditionAncestorId": "D000012327",
            "ConditionAncestorTerm": "RNA Virus Infections"
          },
          {
            "ConditionAncestorId": "D000014777",
            "ConditionAncestorTerm": "Virus Diseases"
          },
          {
            "ConditionAncestorId": "D000012141",
            "ConditionAncestorTerm": "Respiratory Tract Infections"
          },
          {
            "ConditionAncestorId": "D000011024",
            "ConditionAncestorTerm": "Pneumonia, Viral"
          },
          {
            "ConditionAncestorId": "D000011014",
            "ConditionAncestorTerm": "Pneumonia"
          },
          {
            "ConditionAncestorId": "D000008171",
            "ConditionAncestorTerm": "Lung Diseases"
          },
          {
            "ConditionAncestorId": "D000012140",
            "ConditionAncestorTerm": "Respiratory Tract Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M2562",
            "ConditionBrowseLeafName": "COVID-19",
            "ConditionBrowseLeafAsFound": "COVID-19 Infection",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9435",
            "ConditionBrowseLeafName": "Infections",
            "ConditionBrowseLeafAsFound": "Infection",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M5520",
            "ConditionBrowseLeafName": "Communicable Diseases",
            "ConditionBrowseLeafAsFound": "Infection",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M19643",
            "ConditionBrowseLeafName": "Coronavirus Infections",
            "ConditionBrowseLeafAsFound": "Coronavirus Infection",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M21853",
            "ConditionBrowseLeafName": "Disease Attributes",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5707",
            "ConditionBrowseLeafName": "Coronaviridae Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M22838",
            "ConditionBrowseLeafName": "Nidovirales Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16674",
            "ConditionBrowseLeafName": "Virus Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14301",
            "ConditionBrowseLeafName": "RNA Virus Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14130",
            "ConditionBrowseLeafName": "Respiratory Tract Infections",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M13056",
            "ConditionBrowseLeafName": "Pneumonia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M13066",
            "ConditionBrowseLeafName": "Pneumonia, Viral",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10320",
            "ConditionBrowseLeafName": "Lung Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14129",
            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC01",
            "ConditionBrowseBranchName": "Infections"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC08",
            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          }
        ]
      }
    }
  }
}